Macrophage targeted antibodies

S. hi. Rich arris, T A. Olson, and J. m. McPherson Antibody response in patients with Gaucher disease after repealed infusion with macrophage-targeted glucocerehrosidase. 

Badger AM, Newman-Tarr TM, Satterfield JL. Selective immunomodulatory activity of SK F 106615, a macrophage-targeting antiarthritic compound, on antibody and cellular responses in rats and mice. Immunopharmacol 1997 37 53-61. 

Tumor Necrosis Factor There are two types of tumor necrosis factor TNF-a and TNF- 8. Of the two, TNF-a has been studied in more detail. TNF-a is a 157 amino acid polypeptide. It is a mediator of immune regulation, including the activation of macrophages and induction of the proliferation of T cells. Another TNF-a function is its cytotoxic effects on a number of tumor cells. Recent research, however, concentrates on its property in the stimulation of inflammation, particularly in the case of rheumatoid arthritis. Clinical trials are being conducted with drugs to block TNF-a with anti-TNF-a monoclonal antibodies. These antibodies target the excessive levels of TNF-a in the synovial fluid of joints and provide relief to sufferers of rheumatoid arthritis (Exhibit 4.10). 

IgG or IgM antibodies direct the immune response toward the antigen located on a cell (e.g., a red blood cell or thrombocyte). Macrophages, NK cells, and neutrophils are recruited by the antibodies to the site of the antigen on the cell surface and destroy the cell by phagocytosis or lysis. Additionally, complement activation will damage the cell (Fig. 6.32). The result, for example, where red cells are the targets is hemolytic anemia. 

---